

The information in this column is not intended as a definitive treatment strategy but as a suggested approach for clinicians treating patients with similar histories. Individual cases may vary and should be evaluated carefully before treatment is provided. The patient described in this column is a composite with characteristics of several real patients.

Pharmacological management of neuropsychiatric symptoms in patients with major neurocognitive disorders

Dominique Elie, MD, MSc; Soham Rej, MD, MSc

A 73-year-old woman with hypertension, mild cognitive impairment and recurrent falls was brought by police to the emergency department after she threatened her neighbour with a knife for “breaking into her apartment to steal her jewelry.” Her family doctor initiated citalopram (10 mg/d) 2 months previously for anxiety and insomnia, but there was not much improvement as she was still “paranoid” according to her daughter. The physical examination and medical workup were remarkable for bilateral hand tremors, a Mini Mental State Examination (MMSE) score of 24/30, and chronic microvascular changes (a non-specific term that included white matter hyperintensities and other vascular pathology) on brain imaging. Risperidone was initiated and gradually increased to 0.5 mg over 2 weeks with fair response. The patient was later discharged to a long-term care facility, given her persistent fear of being robbed.

Major neurocognitive disorders (NCD), also known as dementias, are increasingly prevalent worldwide.¹ Comorbid neuropsychiatric symptoms (NPS), such as depression, anxiety, apathy, sleep disturbance, agitation, hallucinations and delusions, are extremely common (> 90%) in patients with all NCD subtypes and are usually more prominent in those in advanced stages.^{2,3} An underlying medical condition, unmet needs and environmental factors often contribute to the emergence of NPS, which underlines the importance of ruling them out first.⁴ Non-pharmacological interventions remain the mainstay of treatment for nonurgent NPS, and guidelines suggest limit-

ing pharmacological interventions to severe, dangerous, or highly distressing symptoms.⁵⁻⁷ When medication is required, clinicians are encouraged to follow the “3T” approach: 1) target specific symptoms, 2) titrate dosage upon clinical response and tolerability and 3) time-limit medication use to avoid unnecessary treatment.

Selective serotonin reuptake inhibitors (SSRIs; e.g., citalopram), serotonin-norepinephrine reuptake inhibitors (SNRIs; e.g., venlafaxine), mirtazapine and bupropion are recommended as first-line agents for severe anxiety and depression in patients with NCD.⁸ Emerging evidence also suggests that citalopram could be effective for NCD-associated agitation.⁹ Although SSRIs are relatively safe in older adults, they can increase the risk of falls, fractures, hyponatremia and QTc prolongation (with citalopram/escitalopram), and clinicians should prescribe them cautiously.^{10,11} The second-generation antipsychotics risperidone, aripiprazole, and olanzapine have the best evidence for NCD-associated agitation and psychosis,¹² but concerns about adverse effects (cardio- and cerebrovascular, metabolic, extrapyramidal) and modest efficacy limit their use.¹³⁻¹⁷ The small (2.0%-3.7%) yet significant increase in the absolute risk of all-cause mortality associated with their use can be worrisome for patients and caregivers,^{18,19} which underlines the importance of having an open discussion about the potential risks and benefits of antipsychotics before their initiation.⁵ Their clinical relevance should be re-evaluated every 3-4 months, and the lowest effective dose should be kept if symptoms recur.⁵ Current evidence is controversial regarding the efficacy of quetiapine for NCD-associated agitation and psychosis,²⁰ however, guidelines still recommend its use for psychotic symptoms in patients with Parkinson disease along with cloza-

pine.^{21,22} Other second- and third-generation antipsychotics (e.g., ziprasidone, lurasidone, brexpiprazole) have limited evidence.^{23,24} Pimavanserin, a selective 5-HT_{2A} inverse agonist recently approved for Parkinson psychosis, seems promising, but is available only in the United States.²⁵ Cholinesterase inhibitors should be favoured over antipsychotics in patients with NCD with Lewy bodies, as psychotic symptoms result from cholinergic neurodegeneration, not hyperdopaminergic activity.²⁶ Otherwise, evidence is lacking to recommend for or against the use of cholinesterase inhibitors and memantine for the prevention and treatment of NPS.^{5,7} Robust findings are also lacking to support the use of mood stabilizers²⁷ as opposed to methylphenidate and trazodone, which can be modestly effective.^{28,29} Benzodiazepines should be avoided given their adverse effect profile.³⁰ Overall, more psychopharmacology trials in aging patients with NCD are needed to support clinical treatment best practices.

In this clinical vignette, our patient most likely presented with NCD of mixed etiology, but a parkinsonian disorder had to be ruled out given the presence of tremors and recurrent falls. This diagnosis was excluded by neurology, and delirium also seemed unlikely. Citalopram was thus tapered down over 2 weeks and switched to risperidone, a commonly used antipsychotic in patients with NCD, after a discussion with the daughter, as the patient's anxiety seemed paranoia-related. Given a partial response to risperidone 0.5 mg, the dose should have been further increased while periodically reassessing efficacy and tolerability. This might have delayed the patient's placement into a long-term care facility.

Affiliations: From the Geri-PARTy Research Group, Department of Psychiatry, Jewish General Hospital, McGill University, Montreal, Que., Canada.

Competing interests: S. Rej has received salary support from a Canadian Institute for Health Research Fellowship Award and a Fonds de Recherche Santé Québec Chercheur-Boursier Clinicien Young Investigator Award. No other competing interests declared.

DOI: 10.1503/jpn.170117

References

1. Prince M, Bryce R, Albanese E, et al. The global prevalence of dementia: a systematic review and metaanalysis. *Alzheimers Dement* 2013;9:63-75 e2.
2. McKeith I, Cummings J. Behavioural changes and psychological symptoms in dementia disorders. *Lancet Neurol* 2005; 4:735-42.
3. Borsje P, Wetzels RB, Lucassen PL, et al. The course of neuropsychiatric symptoms in community-dwelling patients with dementia: a systematic review. *Int Psychogeriatr* 2015;27:385-405.
4. Kales HC, Gitlin LN, Lyketsos CG. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel. *J Am Geriatr Soc* 2014; 62:762-9.
5. Reus VI, Fochtmann LJ, Eyler AE, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. *Am J Psychiatry* 2016;173:543-6.
6. National Collaborating Centre for Mental Health. *A NICE-SCIE guideline on supporting people with dementia and their carers in health and social care*. Leicester (UK): The British Psychological Society and Gaskell; 2006.
7. Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. *Can Geriatr J*. 2012;15:120-6.
8. Conn D, Gibson M, McCabe D. CCSMH guidelines update — The assessment and treatment of mental health issues in long-term care homes (focus on mood and behaviour symptoms). Toronto (ON): Canadian Coalition for Seniors' Mental Health; 2014. Available: www.ccsmh.ca (accessed 2017 June 15).
9. Schneider LS, Frangakis C, Drye LT, et al. Heterogeneity of treatment response to citalopram for patients with Alzheimer's disease with aggression or agitation: the CitAD randomized clinical trial. *Am J Psychiatry* 2016;173:465-72.
10. Sultana J, Spina E, Trifiro G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. *Expert Opin Drug Metab Toxicol* 2015;11:883-92.
11. Greenblatt HK, Greenblatt DJ. Antidepressant-associated hyponatremia in the elderly. *J Clin Psychopharmacol* 2016;36:545-9.
12. Seitz DP, Gill SS, Herrmann N, et al. Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review. *Int Psychogeriatr* 2013;25:185-203.
13. Farlow MR, Shamlilian TA. Benefits and harms of atypical antipsychotics for agitation in adults with dementia. *Eur Neuropsychopharmacol* 2017;27:217-31.
14. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. *JAMA* 2011; 306:1359-69.
15. Maglione M, Maher AR, Hu J, et al. *Off-label use of atypical antipsychotics: an update*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011.
16. Hsu WT, Esmaily-Fard A, Lai CC, et al. Antipsychotics and the risk of cerebrovascular accident: a systematic review and meta-analysis of observational studies. *J Am Med Dir Assoc* 2017;18:692-9.
17. Dennis M, Shine L, John A, et al. Risk of adverse outcomes for older people with dementia prescribed antipsychotic medication: a population based e-cohort study. *Neurol Ther*. 2017;6:57-77.
18. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005;294:1934-43.
19. Maust DT, Kim HM, Seyfried LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. *JAMA Psychiatry* 2015;72:438-45.
20. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. *Am J Geriatr Pharmacother* 2010; 8:316-30.
21. American Academy of Neurology. Evaluation and treatment of depression, psychosis and dementia in Parkinson's disease — AAN summary of evidence-based guidelines for clinicians St. Paul (MN): AAN; 2006. Available: http://tools.aan.com/professionals/practice/guidelines/Eval_Treatment_PD_Sum.pdf (accessed 2017 June 15).
22. Grimes D, Gordon J, Snelgrove B, et al. Canadian Guidelines on Parkinson's Disease. *Can J Neurol Sci* 2012;39:S1-30.
23. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. *J Manag Care Pharm* 2012;18:S1-20.
24. Porsteinnsson AP, Antonsdottir IM. An update on the advancements in the treatment of agitation in Alzheimer's disease. *Expert Opin Pharmacother* 2017;18:611-20.
25. Combs BL, Cox AG. Update on the treatment of Parkinson's disease psychosis: role of pimavanserin. *Neuropsychiatr Dis Treat* 2017;13:737-44.
26. O'Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: a revised (third) consensus statement from the British Association for Psychopharmacology. *J Psychopharmacol* 2017;31:147-68.
27. Yeh YC, Ouyang WC. Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review. *Kaohsiung J Med Sci* 2012;28:185-93.
28. Theleritis C, Siarkos K, Katirtzoglou E, et al. Pharmacological and nonpharmacological treatment for apathy in Alzheimer disease: a systematic review across modalities. *J Geriatr Psychiatry Neurol* 2017; 30:26-49.
29. McClam TD, Marano CM, Rosenberg PB, et al. Interventions for neuropsychiatric symptoms in neurocognitive impairment due to Alzheimer's disease: a review of the literature. *Harv Rev Psychiatry* 2015; 23:377-93.
30. Defrancesco M, Marksteiner J, Fleischhacker WW, et al. Use of benzodiazepines in Alzheimer's disease: a systematic review of literature. *Int J Neuropsychopharmacol* 2015;18:pyv055.